Lee Greenberger on Newly Approved Drugs for Multiple Myeloma

Article

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma.

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses new agents that were recently approved for multiple myeloma.

Three drugs were FDA approved within 3 weeks — Darzalex (daratumumab), Ninlaro (ixazomib), and Empliciti (elotuzumab). Darzalex and Empliciti are antibodies, and Ninlaro is a proteasome inhibitor.

The agents can be used as monotherapy or in combination with conventional therapy, Greenberger explains. They have also extended progression-free survival in patients with myeloma.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
2 experts are featured in this series.
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
2 experts are featured in this series.
Image of a woman with shoulder-length black hair wearing headphones and a white sweater
Related Content
Image of a B cell

Single-Center Study Backs CD19 CAR T in B-Cell Cancers

Caroline Seymour
April 7th 2025
Article

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell malignancies in real-world data.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

light blue background with a white outline indicating blood cells

Positive Responses to Liso-Cel Observed in Relapsed/Refractory Marginal Zone Lymphoma

Ashling Wahner
February 16th 2025
Article

Lisocabtagene maraleucel demonstrated a statistically significant overall response rate in adults with relapsed/refractory marginal zone lymphoma.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Simple white line illustration of red blood cells on a yellow background

Evaluating the Risk of Second Primary Cancers After CAR T-Cell Therapy

Ashling Wahner
January 30th 2025
Article

The association of CAR T-cell therapies with second primary cancers warrants the development and examination of mitigation strategies for these toxic effects.

green background with blue text indicating FDA and green text indicating approved with a green checkmark

FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS

Bridget Hoyt
January 24th 2025
Article

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic stem cell transplantation.